1. |
Optimising the management of lung cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
Management of procedural pain in paediatric oncology |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
HAART introduction in Italy provides cost, QOL advantage |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Anastrozole of global value in early breast cancer? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 5-6
L Hunt,
Preview
|
|
摘要:
In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, tamoxifen is associated with a number of adverse events that can limit its use. Adjuvant treatment with anastrozole [Arimidex] in postmenopausal women with early-stage breast cancer in the ATAC*trial was associated with superior efficacy, compared with tamoxifen, in terms of disease-free survival, time to recurrence, and the incidence of contralateral breast cancer. Furthermore, anastrozole has numerous noteworthy advantages in terms of tolerability compared with tamoxifen.1Several recent presentations at the 6th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting [Barcelona, Spain; November 2003] and the 26th Annual San Antonio Breast Cancer Symposium [Texas, US; December 2003] presented the results of pharmacoeconomic and outcome analyses of the ATAC study from the perspective of a number of countries.2,3,4,5,6Overall, the studies suggest that anastrozole is a cost-effective alternative to tamoxifen for the treatment of hormone-receptor positive (HR+) breast cancer tumours, and is within acceptable limits for reimbursement. This cost effectiveness is consistent across several countries with different healthcare systems.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
Diltiazem saves drug costs in renal transplant recipients |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
Ranolazine: long-term survival effect in severe angina |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
Onapristone for Charcot-Marie-Tooth disease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
News from the 76th Annual Scientific Sessions of the American Heart Association |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 10-11
RM Poole,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
Cisplatin-based adjuvant therapy improves survival in NSCLC |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
Rofecoxib: no benefit in Alzheimer's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1422,
2004,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|